- Home
- ATNI vs PROK Comparison
ATNI vs PROK Comparison
Compare ATNI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNI | PROK |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.5M | 359.4M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATNI | PROK |
|---|---|---|
| Price | $25.74 | $1.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 67.0K | ★ 1.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | ★ 34.29 | N/A |
| EPS | ★ 10.44 | N/A |
| Revenue | ★ $727,975,000.00 | $893,000.00 |
| Revenue This Year | $1.34 | N/A |
| Revenue Next Year | $1.90 | $7.83 |
| P/E Ratio | $2.46 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $14.16 | $1.30 |
| 52 Week High | $33.41 | $3.48 |
Technical Indicators
Market Signals| Indicator | ATNI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 36.05 |
| Support Level | $25.03 | $1.30 |
| Resistance Level | $27.73 | $1.76 |
| Average True Range (ATR) | 1.02 | 0.11 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 7.34 | 14.29 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.